These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34790117)

  • 1. Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy.
    Li W; Zhou Y; Wu Z; Shi Y; Tian E; Zhu Y; Wang T; Dou W; Meng X; Chen M; Zhai B; Zhu D
    Front Pharmacol; 2021; 12():724306. PubMed ID: 34790117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
    Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
    Qin D; Li D; Zhang B; Chen Y; Liao X; Li X; Alexander PB; Wang Y; Li QJ
    Oncoimmunology; 2020 Aug; 9(1):1806009. PubMed ID: 32923168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of chimeric antigen receptor‑modified T cells targeting EpCAM and assessment of their anti‑tumor effect on cancer cells.
    Zhou Y; Wen P; Li M; Li Y; Li XA
    Mol Med Rep; 2019 Sep; 20(3):2355-2364. PubMed ID: 31322180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
    Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
    Front Immunol; 2021; 12():638639. PubMed ID: 34177890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells.
    Soto KEG; Loureiro LR; Bartsch T; Arndt C; Kegler A; Mitwasi N; Drewitz L; Hoffmann L; Saleh HA; Crespo E; Mehnert M; Daglar C; Abken H; Momburg F; Bachmann M; Feldmann A
    Front Immunol; 2023; 14():1302354. PubMed ID: 38169746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer.
    Jung M; Yang Y; McCloskey JE; Zaman M; Vedvyas Y; Zhang X; Stefanova D; Gray KD; Min IM; Zarnegar R; Choi YY; Cheong JH; Noh SH; Rha SY; Chung HC; Jin MM
    Mol Ther Oncolytics; 2020 Sep; 18():587-601. PubMed ID: 32995483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
    Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
    Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors.
    Li D; Guo X; Yang K; Yang Y; Zhou W; Huang Y; Liang X; Su J; Jiang L; Li J; Fu M; He H; Yang J; Shi H; Yang H; Tong A; Chen N; Hu J; Xu Q; Wei YQ; Wang W
    Sci Adv; 2023 Dec; 9(48):eadg9721. PubMed ID: 38039357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
    Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
    Front Immunol; 2017; 8():1850. PubMed ID: 29312333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.